Navigation Links
UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
Date:6/13/2012

WORCESTER, MA Juan I. Fuxman Bass, PhD, a postdoctoral scholar at the University of Massachusetts Medical School, was named a 2012 Pew Latin American Fellow in the Biomedical Sciences today by The Pew Charitable Trusts. The program provides support for young scientists from Latin America to pursue postdoctoral training in the United States and establish their own labs upon returning to their home countries. Dr. Fuxman Bass joins 10 other researchers named to this year's class.

These scientists have dedicated their careers to finding solutions for some of the world's most troubling health problems. This fellowship will provide support that will further their research, enable them to work with colleagues in the United States, and increase scientific knowledge throughout their home region. While the number of foreign doctorate recipients staying in the United States has never been higher more than 60 percent according to the National Science Foundation more than 70 percent of Pew Latin American Fellows return to their country to help build the scientific infrastructure throughout the hemisphere.

"Being named a Pew Latin American Fellow is a tremendous honor and a huge opportunity for me," said Dr. Fuxman Bass, a postdoctoral scholar in the lab of Marian Walhout, PhD, professor of molecular medicine and co-director of the Program in Systems Biology, where he is studying the complex, cell-to-cell communication system that the immune system uses to tailor its defense against pathogens. "There aren't many labs working on systems biology in Argentina. This fellowship provides the training and start-up funding I'll need to establish my own lab and advance the field of systems biology in Argentina."

To coordinate an effective defense against pathogens, immune cells communicate with each other by releasing chemical signals called cytokines. The production of these signals is tightly regulated by the immune system and is greatly dependent on
'/>"/>

Contact: Jim Fessenden
james.fessenden@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings
2. NIST/UMass study finds evidence nanoparticles may increase plant DNA damage
3. Chemical engineers at UMass Amherst find high-yield method of making xylene from biomass
4. UMass Amherst wildlife researcher photographs rare Sumatran rabbit
5. Miniature pressure sensors for medical touch
6. Research!America says house funding levels for FY13 could undermine medical progress
7. Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship
8. Medical device, health professionals attend first national conference on value-driven engineering
9. Ultrasensitive biosensor promising for medical diagnostics
10. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
11. Tufts Medical Center researchers finds marker in premies saliva predicts readiness to feed by mouth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... 35 headwater basins in the United States and Canada found ... was less than expected in many locations, suggesting that some ... The study was just published in a special issue ... Ecological Research (LTER) network of 26 sites around the country ...
... new Rice University study this week in the journal Science ... -- from the realms of tectonic plates down to molecular bonds ... below ground. "Everything throughout history shows us that Earth does ... said Rice geochemist Cin-Ty Lee, the lead author of the study. ...
... New England is expected to experience a "moderate" regional ... in the Gulf of Maine to study the toxic algae ... no direct threat to human beings, however the toxins they ... clams which can cause paralytic shellfish poisoning (PSP) in humans ...
Cached Biology News:Impact of warming climate doesn't always translate to streamflow 2Copper chains: Study reveals Earth's deep-seated hold on copper 2Copper chains: Study reveals Earth's deep-seated hold on copper 3Researchers report potential for a 'moderate' New England 'red tide' in 2012 2Researchers report potential for a 'moderate' New England 'red tide' in 2012 3Researchers report potential for a 'moderate' New England 'red tide' in 2012 4
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... over the Badger state pavilion at the annual BIO convention ... visit the New York State exhibit to breathe gardenia-scented oxygen ... has grown to be as competitive as biotechnology, most states, ... the crowd. Welcome to the world of bio-branding. , ,Wisconsins ...
... DEMOletter know that I've written regularly about so- called social ... columns have run under titles such as "I'm LinkedIn - ... networks to both user and investor. I wasn't being critical, ... model for these services. , ,But in recent weeks, ...
... is currently undergoing a historical transformation. Such ... War I, when the paper, brewing, automotive and ... , ,The change from an agriculture and manufacturing-based ... is inevitable. Wisconsin now finds itself competing ...
Cached Biology Technology:Whats in a name? Quite a bit, when youre competing in biotech 2Social networks and my big a-ha 2Social networks and my big a-ha 3Social networks and my big a-ha 4Educate, innovate and execute: Wisconsins model for success 2Educate, innovate and execute: Wisconsins model for success 3
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
HIV-1 TAT (vN-21)...
Biology Products: